Gyre Therapeutics, Inc. Accrued Liabilities and Other Liabilities
Gyre Therapeutics, Inc. (GYRE) had Accrued Liabilities and Other Liabilities of $18.81 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedLiabilitiesAndOtherLiabilities · last filed 2026-08-07
- 2026-06-30: Accrued Liabilities and Other Liabilities $18.81M.
- 2026-03-31: Accrued Liabilities and Other Liabilities $15.41M.
- 2025-12-31: Accrued Liabilities and Other Liabilities $18.16M; Accrued Liabilities and Other Liabilities as first filed $14.35M.
- 2025-09-30: Accrued Liabilities and Other Liabilities $11.80M.
| Period end | Accrued Liabilities and Other Liabilities | Accrued Liabilities and Other Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $18.81M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $15.41M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $18.16M 10-Q · filed 2026-08-07 | $14.35M 10-K · filed 2026-03-13 |
| 2025-09-30 | $11.80M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $14.92M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $17.24M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $10.62M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $9.55M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $10.51M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $10.77M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $11.94M 10-K · filed 2025-03-17 | |
| 2022-12-31 | $9.26M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |